Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Finds Clue to Sunburn-Melanoma Link

June 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 6
Volume 8
Issue 6

NEW YORK-The association between intermittent but intense sun exposure and malignant melanoma has long been recognized, though the reasons behind it have not been understood. Researchers have now uncovered mechanisms likely to explain why this specific pattern of sun exposure leads to the deadliest form of skin cancer.

NEW YORK—The association between intermittent but intense sun exposure and malignant melanoma has long been recognized, though the reasons behind it have not been understood. Researchers have now uncovered mechanisms likely to explain why this specific pattern of sun exposure leads to the deadliest form of skin cancer.

Barbara Gilchrest, MD, professor of dermatology, Boston University, and author of “Mechanisms of Disease,” a review published in the New England Journal of Medicine (April 29, 1999), summarized her findings at an American Academy of Dermatology briefing.

Melanoma typically occurs in areas of the body intermittently exposed to the sun, the middle of the back being the most common site. This is in contrast to squamous cell and basal cell carcinomas, the two most common skin cancers, which tend to occur in regularly sun-exposed areas such as the face, back of the hands, and forearms, and in people with a history of cumulative exposure over the course of many years.

Specific DNA mutations due to ultraviolet damage are involved in all skin cancers, she said, but the difference lies in the mechanism by which the body repairs or counteracts that DNA damage.

Squamous and basal cell carcinomas arise in the keratinocytes, whereas melanoma is a cancer of the melanocytes. When exposed to UV radiation, the most severely damaged keratinocytes undergo apoptosis, while those less severely damaged remain and continue to be vulnerable to mutation with each subsequent exposure. Melanocytes, on the other hand, are highly resistant to apoptosis, possibly because they exist in far fewer numbers than keratinocytes and serve the important and irreplaceable function of producing the protective pigment melanin. “This resistance to cell death enables UV-damaged melanocytes to mutate and divide,” Dr. Gilchrest said.

Furthermore, later DNA damage in human skin cells may be repaired to an enhanced degree through a process known as the SOS response. The production of specialized repair proteins is increased within 2 to 3 days of an initial damaging sun exposure, and parallels increased production of melanin pigment, resulting in a tan.

The repair process is not perfect, however, and cells with DNA defects continue to accumulate, accounting for the pattern of cumulative damage associated with the nonmelanoma skin cancers.

A large dose of UV, such as results in a severe sunburn rather than gradual tanning, damages keratinocytes and melanocytes alike. The difference is that the highly damaged keratinocytes undergo apoptosis, whereas the melanocytes remain in their damaged state.

According to Dr. Gilchrest’s hypothesis, “intermittent high-dose exposures are expected to give rise to more melanomas than frequent low-dose exposures because the UV injury occurs when the melanocytes’ DNA-repair capacity is relatively low, the DNA damage is poorly repaired, and all the damaged cells are retained.”

The incidence of malignant melanoma has risen 1,900% since 1930, a trend Dr. Gilchrest attributes to the increase in recreational exposure to skin areas left covered in the past. Excessive sun exposure and severe sunburns in the first 10 to 15 years of life can result in a threefold increase in the lifetime risk of developing melanoma, she said.

The Academy urges sun avoidance, the use of protective clothing and a sunscreen with an SPF of at least 15 when the sun cannot be avoided, regular examination of all areas of the skin, and an annual skin examination by a professional.

Articles in this issue

Opioids Are Often Ignored for Treating Neuropathic Pain
Study Suggests Short Time Interval for Ovarian Cancer Screening
Your Strengths, Market’s Demands Dictate Marketing Strategies
First-Line Irinotecan Effective in Advanced Colorectal Cancer
Doctor Ponders Popularity of Alternative Medicine
Can Physicians Be Held Liable for Alternative Medicine?
Tips on Marketing Your Oncology Practice to Patients
Biologics Research Promises ‘Synergistic’ Cancer Therapy
Patient Care Costs of Clinical Trials May Be Less Than Standard Care
Sentinal Node Biopsy Finds 98% of Metastic Colon Cancers
Church-Based Project Provides Cervical Cancer Screening for Latinas
Treatment of Actinic Keratoses Is More Than Cosmetic Issue
Radiopharmaceuticals Effective Therapy for Metastatic Bone Pain
Surgery Still Standard of Care for FAP, HNPCC
New Approaches to CIN in HIV-Positive Women Reported

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Allison Betof Warner, MD, PhD, with the Oncology Brothers presenting slides
Experts on myeloma
Related Content

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Ashley Chan
June 12th 2025
Article

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Tim Cortese
June 1st 2025
Article

The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.


Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma

Roman Fabbricatore
June 1st 2025
Article

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Related Content

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

Encorafenib Combo May Limit Recurrence Risk in BRAF V600+ Melanoma

Ashley Chan
June 12th 2025
Article

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.


OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.


Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Ashley Chan
June 8th 2025
Article

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.


On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.


Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Nivolumab/Relatlimab Elicit IC Activity in Anti–PD-L1–Refractory Melanoma Brain Mets

Tim Cortese
June 1st 2025
Article

The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.


Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Relatlimab Shows Comparable Efficacy to Ipilimumab in Advanced Melanoma

Roman Fabbricatore
June 1st 2025
Article

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.